(Q44783623)

English

Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

scientific article published in March 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 December 2017

Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies (English)

1 reference

Europe PubMed Central

6 December 2017

1 reference

based on heuristic

inferred from title

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

6 December 2017

author name string

Idilman R

1

1 reference

Europe PubMed Central

6 December 2017

Soydan E

3

1 reference

Europe PubMed Central

6 December 2017

Törüner M

4

1 reference

Europe PubMed Central

6 December 2017

Soykan I

5

1 reference

Europe PubMed Central

6 December 2017

Akbulut H

6

1 reference

Europe PubMed Central

6 December 2017

Arslan O

7

1 reference

Europe PubMed Central

6 December 2017

Ozcan M

8

1 reference

Europe PubMed Central

6 December 2017

Türkyilmaz AR

9

1 reference

Europe PubMed Central

6 December 2017

Bozdayi M

10

1 reference

Europe PubMed Central

6 December 2017

Karayalçin S

11

1 reference

Europe PubMed Central

6 December 2017

Van Thiel DH

12

1 reference

Europe PubMed Central

6 December 2017

Ozden A

13

1 reference

Europe PubMed Central

6 December 2017

Beksaç M

14

1 reference

Europe PubMed Central

6 December 2017

Akan H

15

1 reference

Europe PubMed Central

6 December 2017

publication date

1 March 2004

1 reference

Europe PubMed Central

6 December 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

6 December 2017

11

1 reference

Europe PubMed Central

6 December 2017

2

1 reference

Europe PubMed Central

6 December 2017

141-147

1 reference

Europe PubMed Central

6 December 2017

Hepatitis B virus infection in allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00479.X

21 January 2018

Identifiers

10.1046/J.1365-2893.2003.00479.X

1 reference

Europe PubMed Central

6 December 2017

1 reference

Europe PubMed Central

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44783623&oldid=2041110018"